Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jobelyn in Schizophrenia
NCT02240173Phase 2Unknown
- Sponsor
- Federal Neuro-Psychiatric Hospital, Yaba
- Start
- Jun 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing Jobelyn + Haloperidol with Haloperidol + Placebo (2 arms). Primary endpoint: Changes in psychotic symptoms at 8 weeks. Status: unknown.
02
Drugs
jobelyn
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02240173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02240173.